Find a Clinical Trial by Adult Cancer Type

Adult Cancers
Childhood Cancers
Doctor
Drug
Phase

Back to Adult Cancers

Cancer Type: Pancreas

54 protocol(s) meet the specified criteria. Please click on the protocol number to get more information about the trial.

Show: Only Pancreas specific trials All trials that include Pancreas

Doctor	Protocol No.	Title
Asher, Arash	IIT2019-08-ASHER-VOXXSOCK	IIT2019-08-ASHER-VOXXSOCK: Voxx Human Performance Technology Socks for Chemotherapy-Induced Peripheral Neuropathy: A Double Blind, Randomized, Controlled Crossover Trial (IRB #236)
Balmanoukian, Ani	GO39733	GO39733 : A phase IA/IB open-label, dose-escalation study of the safety and pharmacokinetics of RO7198457 as a single agent and in combination with atezolizumab in patients with locally advanced or metastatic tumors (IRB#49235)
Balmanoukian, Ani	204691	204691: A Phase I Open Label study of GSK3359609 administered alone and in combination with anticancer agents in subjects with selected advanced solid tumors (IRB:54166)
Balmanoukian, Ani	SGN228-001	A phase 1 study of SGN-CD228A in select advanced solid tumors (IRB#138)
Chiu, Vi K.	226688	226688: An Open Label, Multicenter, Safety and Efficacy Phase 2 Study of PRL3-Zumab in Solid Tumors (IRB#933)
Gaddam, Srinivas	IIT2019-22-GADDAM-LUMASON	IIT2019-22-GADDAM-LUMASON: The Role of Contrast Enhanced Endoscopic Ultrasound for Evaluation of Pancreas Lesions (IRB#259)
Gaddam, Srinivas	IIT2019-24-GADDAM-SHEARWAVE	IIT2019-24-GADDAM-SHEARWAVE: Prospective Study of Shear Wave Elastography of the Pancreas using Endoscopic Ultrasound (STUDY00000322)
Goodarzi, Mark	EIIT-CPDPC16-04	CPDPC16-04: Evaluation of a mixed meal test for Diagnosis and characterization of Type 3c diabetes mellitus secondary to pancreatic cancer and chronic pancreatitis (DETECT) (IRB#50528)
Gresham, Gillian	IIT2020-13-GRESHAM-ELLY	IIT2020-13-GRESHAM-ELLY: Evaluating the effect of a mobile audio companion (Elly) to reduce anxiety in cancer patients (IRB#943)
Gresham, Gillian	IIT2018-19-GRESH-DIGISTEP	Digitally-captured Step counts for Evaluating Performance Status in Advanced Cancer Patients: A single cohort, prospective trial (Digi-STEPS) (IRB#55271)
Gutierrez, Rodolfo	TYR-219-01	A Phase 1/2 Study with Open-Label, Dose Escalation Phase Followed by Single-Arm Expansion at the Maximum Tolerated Dose to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of NT219 Injection alone and in Combination with ERBITUX® (Cetuximab) in Adults with Advanced solid tumors and Head and Neck cancer (IRB#907)
Hamid, Omid	D8510C00001	D8510C00001: A Phase 1, Open-label, Dose-escalation and Expansion Study of MEDI1191 Administered Intratumorally as Monotherapy and in Combination with Durvalumab in Subjects with Advanced Solid Tumors (IRB#57295)
Hamid, Omid	212214	212214: A Phase 1 First-Time-in-Human, Open-Label Study of GSK6097608 Administered as Monotherapy and in Combination with Anticancer Agents in Participants with Advanced Solid Tumors (IRB#688)
Hamid, Omid	R3767-ONC-1613	R3767-ONC-1613: A Phase 1, Open-Label, Dose-Escalation and Cohort Expansion First-in-Human Study of the Safety, Tolerability, Activity and Pharmacokinetics of REGN3767 (anti-LAG-3 mAb) Administered Alone or in Combination with REGN2810 (anti-PD-1 mAb) in Patients with Advanced Malignancies (IRB#48031)
Hamid, Omid	RTX-240-01	PHASE 1/2 STUDY OF RTX-240 MONOTHERAPY (IRB#596)
Hamid, Omid	BDB001-102	BDB001-102 : A Phase 1 Open-label Dose Escalation Study of BDB001 in Combination with Atezolizumab in Subjects with Advanced Solid Tumors (IRB#397)
Hamid, Omid	EZH-108	EZH-108: A Phase I, Open-Label Multi-Dose Two-Part Study to Characterize The Effects of a Strong CYP3A4 Inhibitor on the Steadystate Pharmacokinetics of Tazemetostat (EPZ-6438), And The Effects Of a Strong CYP3A4 Inducer on the Steady-State Pharmacokinetics of Tazemetostat in Subjects with Advanced Malignancies (IRB#810)
Hamid, Omid	CART-TNMUC1-01	CART-TnMUC1-01: A Phase 1 Open-Label, Multi-Center First in Human Study of TnMUC1-Targeted Genetically-Modified Chimeric Antigen Receptor T Cells in Patients with Advanced TnMUC1-Positive Solid Tumors and Multiple Myeloma (IRB#12345)
Hamid, Omid	CIBI322A102	CIBI322A102 A Phase 1a study evaluating the safety, tolerability and preliminary efficacy of IBI322 in subjects with advanced malignant tumors. (IRB#1021)
Hamid, Omid	BA3011-001	BA3011-001: A Phase 1/2 Dose Escalation and Dose Expansion Study of BA3011 in Patients with Advanced Solid Tumors( IRB#383)
Hamid, Omid	ALKS4230-001	ALKS4230-001: A Phase 1/2 Study of ALKS 4230 Administered Subcutaneously as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors- ARTISTRY-2 (001)(IRB#0539)
Hamid, Omid	TAPUR	Targeted Agent and Profiling Utilization Registry (TAPUR) Study (IRB#49119)
Hamid, Omid	587-00	587-00: A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial. (IRB#54410)
Hendifar, Andrew	RGX-202-001	RGX-202-001: A Phase 1 Study of RGX-202-01, a Small Molecule Inhibitor of the Creatine Transporter, SLC6a8, with or without FOLFIRI in Patients with Advanced Gastrointestinal Malignancies with Select Expansion Cohorts (IRB#55176)
Hendifar, Andrew	IIT2018-29-HENDIFAR-PNCX3	IIT2018-29-Hendifar-PNCX3: PANCREATIC-ENZYME REPLACEMENT THERAPY WITH PANCREAZE (PANCRELIPASE) DELAYED-RELEASE IN ADDITION TO STANDARD OF CARE FOR BORDERLINE RESECTABLE, LOCALLY ADVANCED, ADVANCED, AND UNRESECTABLE PANCREATIC ADENOCARCINOMA PATIENTS (PANCAX-3) WITH CACHEXIA AND EXOCRINE PANCREATIC INSUFFICIENCY (IRB#208)
Hendifar, Andrew	MK-3475-158	MK-3475-158-00: A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors (KEYNOTE 158) (IRB#43687)
Hendifar, Andrew	MK-7339-002	MK7339-002: A Phase 2 Study of Olaparib Monotherapy in Participants with Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (IRB#57241)
Hendifar, Andrew	18-0402	18-0402: A Phase 1a/b Dose-Escalation Study Followed by Expansion Cohorts of NGM120, a GFRAL Antagonist Monoclonal Antibody Blocking GDF15 Signaling, in Subjects with Advanced Solid Tumors and Pancreatic Cancer using Combination Therapy (IRB#0185)
Hendifar, Andrew	XMAB18087-01	XmAb18087-01: A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb®18087 in Subjects with Advanced Neuroendocrine and Gastrointestinal Stromal Tumors (IRB#52197)
Hendifar, Andrew	EIIT-MENAC-2017-03	EIIT-MENAC-2017-03: A Randomised, Open-Label Trial Of a Multimodal Intervention (Exercise, Nutrition And Antiinflammatory Medication) Plus Standard Care Versus Standard Care Alone to Prevent / Attenuate Cachexia in Advanced Cancer Patients Undergoing Chemotherapy (IRB#55738)
Hendifar, Andrew	EF-27	EF-27/PANOVA 3: A Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally advanced pancreatic adenocarcinoma (IRB#456)
Hitchins, Megan	IIT2017-13-HITCHINS-UCFC	IIT2017-13-HITCHINS-UCFC: Identifying cryptic causes for high-risk hereditary cancer syndromes and their role in cancer causation. (IRB#49624)
Labadzhyan, Artak	IIT2016-09-LABADZHYAN-ICI	IIT2016-09-LABADZHYAN-ICI: Prospective study of predictive markers and changes in specific endocrine hormones in patients with metastatic cancers treated with immune checkpoint inhibitors. (IRB#45026)
Lo, Simon	NANOPAC-2016-05	NANOPAC-2016-05: Phase IIa Trial Evaluating the Safety of Intratumoral Injection of NanoPac in Subjects with Locally Advanced Pancreatic Adenocarcinoma (IRB#49989)
Mita, Monica	MT-5111-001	MT-5111_001: A Phase 1 open-label, multicenter dose escalation study of MT-5111 in subjects with previously treated advanced HER2-positive solid tumors (IRB#144)
Mita, Monica	8379643	8379643: A Phase 1, Multicenter, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Evidence of Antitumor Activity of ZZ06 in Adult Patients with Advanced EGFR positive Solid Tumor Malignancies (IRB#632)
Mita, Monica	SQZ-PBMC-HPV-101	SQZ-PBMC-HPV-101: A Phase 1, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of SQZ-PBMC-HPV as Monotherapy and in Combination with Atezolizumab in HLA-A*02+ Patients with HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors (IRB#577)
Mita, Alain	ASTX029-01	ASTX029-01: A Phase 1-2 Study of the Safety, Pharmacokinetics, and Activity of ASTX029 in Subjects With Advanced Solid Tumors (IRB#54467)
Mita, Alain	ASTX295-01	ASTX295-01: Phase 1/2 Open-Label Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX295 in Subjects with Wild-Type TP53 Advanced Solid Tumors (IRB#016)
Mita, Monica	RGX-104-001	A Phase 1 Study of RGX-104, a Small Molecule LXR Agonist, in Patients with Advanced Solid Malignancies and Lymphoma with an Expansion in Select Malignancies (IRB#46271)
Mita, Alain	P1719-SUR-Z11	P1719-SUR-Z11: A Phase 2, Open-label, Multicenter, Study of an Immunotherapeutic Treatment, DPX-Survivac in combination with Low Dose Cyclophosphamide and Pembrolizumab, in Subjects with Selected Advanced and Recurrent Solid Tumours. (IRB#57155)
Mita, Monica	OBT076-001	OBT076-001: A Phase 1, open-label, dose finding study to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of OBT076, a CD205-directed antibody drug conjugate, in recurrent and/or metastatic CD205-positive solid tumors and in women with CD205-positive HER2-negative metastatic breast cancer (IRB#076)
Mita, Alain	BNT411-01	BNT411-01: Phase 1/2a, first-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of BNT411 as a monotherapy in patients with solid tumors and in combination with atezolizumab, carboplatin and etoposide in patients with chemotherapy-naïve extensive-stage small cell lung cancer (ES-SCLC) (IRB#578)
Mita, Monica	M16-573	M16-573: A Phase 1 First-in-Human Study with ABBV-155 Alone and in Combination with Taxane Therapy in Adults with Relapsed and/or Refractory Solid tumors (IRB#24)
Mita, Monica	LNS-101	LNS-101: A Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of LNS8801 in Patients With Advanced Cancer (IRB#315)
Mita, Alain	EAY131	EAY131: Molecular Analysis for Therapy Choice (MATCH) (IRB#41419)
Mita, Monica	GEN-602-CT-101	GEN-602-CT-101: A Phase I, Multicenter, Open-label, Dose-Escalation, Safety, Pharmacodynamic and Pharmacokinetic Study of GZ17-6.02 Given orally on a daily x 21 days followed by 7 Days off schedule in patients with Advanced Solid Tumors or Lymphoma (IRB#56184)
Osipov, Arsen	A021806	A021806: A Phase III Trial of Perioperative versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer (IRB#1039)
Pandol, Stephen	EIIT2019-PANDOL-MINIMAP	EIIT2019-Pandol-MINIMAP: Magnetic Resonance Imaging as a Non- Invasive Method for the Assessment of Pancreatic Fibrosis (MINIMAP) (IRB #5)
Posadas, Edwin	BB-UOP-42197-BLOOD-BANK	Urologic Oncology Program Blood Specimen Repository (IRB # 42197)
Reckamp, Karen	ELVCAP-001-01	ELVCAP-001-01: A Phase 2 Study of Seribantumab in Adult Patients with Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors (IRB#862)
Shiao, Stephen	IIT2016-18-SHIAO-NEOADSRS	IIT2016-18-SHIAO-NEOADSRS: Neoadjuvant radiosurgery for the treatment of metastatic brain tumors (IRB#47027)
Sicotte, Nancy	BA39731	BA39731: An Observational Study of Ocrelizumab-Treated Patients With Multiple Sclerosis to Determine the Incidence and Mortality Rates of Breast Cancer and All Malignancies (Verismo Study) (IRB#482)
Wentzel, Kristopher	9801-CL-0101	9801-CL-0101: A Phase 1, Open-label Study of ASP9801, an Oncolytic Virus, Administered by Intratumoral Injection in Patients with Advanced/Metastatic Solid Tumors (IRB#57758)

New studies open frequently, please check back for updates

The following physicians have trials which are currently recruiting patients. If you do not see the doctor you are searching for, please call 310-423-2133 for more information.

Phase I

Researchers test an experimental drug or treatment in a small group of people (20-80), to evaluate its safety and identify side effects. Often these trials are not disease specific and may include more than one type of cancer.

Phase II

The experimental drug or treatment is administered to a larger group of people (100-300) to determine its effectiveness and to further evaluate its safety.

Phase III

The experimental drug or treatment is administered to larger groups of people (1,000-3,000) to confirm its effectiveness, monitor side effects, compare it with standard or equivalent treatment, and collect information that will allow the experimental drug or treatment to be used safely.